scholarly journals UPLC-Q-TOF/MS-Based Plasma Metabolomics to Evaluate the Effects of Aspirin Eugenol Ester on Blood Stasis in Rats

Molecules ◽  
2019 ◽  
Vol 24 (13) ◽  
pp. 2380 ◽  
Author(s):  
Dongshuai Shen ◽  
Ning Ma ◽  
Yajun Yang ◽  
Xiwang Liu ◽  
Zhe Qin ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Blood Viscosity ◽  
Metabolic Profile ◽  
Blood Stasis ◽  
Thromboxane A2 ◽  
Plasma Viscosity ◽  
Inhibit Platelet Aggregation ◽  
Underlying Mechanisms ◽  
Aspirin Eugenol Ester ◽  
Metabolomic Study

Aspirin eugenol ester (AEE) is a novel compound that is formed from the esterification of aspirin (acetylsalicylic acid (ASA)) and eugenol. This study aimed to investigate the effects of AEE on blood stasis in rats and to characterize the underlying mechanisms using a plasma metabolomic study. The results indicate that AEE and ASA could modulate whole blood viscosity (WBV), plasma viscosity (PV), blood coagulation parameters, platelet count, platelet aggregation, lactate dehydrogenase (LDH), creatinine (CR) and the levels of thromboxane A2 (TXA2) and 6-keto prostaglandin F1α (6-keto-PGF1α). The metabolic profiles of the plasma samples from all groups were clearly separated in the score plots. Nineteen potential metabolites were selected and identified, and disordered levels of these metabolites could be regulated by AEE and ASA. Pathway analysis showed that the mechanism of action of AEE on blood stasis might be principally related to the metabolism of amino acid, fatty acid, energy and glycerophospholipid. The above results indicate that AEE protected the rats against blood stasis, and that this effect might have been caused by the anticoagulation activity of AEE and its abilities to maintain a balance between TXA2 and PGI2, reduce blood viscosity, inhibit platelet aggregation and normalize the plasma metabolic profile.

scholarly journals Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition

2010 ◽  
Vol 638 (1-3) ◽  
pp. 5-12 ◽  
Author(s):  
Fernanda C.F. Brito ◽  
Arthur E. Kummerle ◽  
Claire Lugnier ◽  
Carlos A.M. Fraga ◽  
Eliezer J. Barreiro ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Cyclic Nucleotides ◽  
Thromboxane A2 ◽  
Inhibit Platelet Aggregation ◽  
Synthesis Inhibition

Suppression Of Platelet Aggregation By A New Beta-Adrenergic Blocker

1981 ◽  
Author(s):  
M Small ◽  
J T Douglas ◽  
Morna Orr ◽  
G D O Lowe ◽  
C D Forces ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Blood Viscosity ◽  
Beta Blockers ◽  
Protective Action ◽  
Plasma Viscosity ◽  
Significant Inhibition ◽  
Variable Effect ◽  
Adrenergic Blocker ◽  
Artery Disease ◽  
Long Acting

Beta-blockers have been reported to have a variable effect on a number of haemostatic parameters. In view of their possible protective action in coronary artery disease, we studied the effect of the new long-acting beta-blocker, carteolol, on platelet function, coagulation and blood viscosity in 10 healthy male volunteers. Following carteolol (5 mg. orally) blood was taken at 2, 5 and 24 hours and we were able to demonstrate a significant inhibition of platelet aggregation to ADP, adrenaline and collagen (p< 0.05) at 5 hours post ingestion, but not at 2 or 24 hours. Platelet release as measured by plasma levels of beta-thromboglobulin, platelet count, fibrinopeptide A, whole blood viscosity and plasma viscosity was also unaltered.

Arachidonate Metabolism And Platelet Disaggregation (DA)-Reaggregation (RA)

1981 ◽  
Author(s):  
Gundu H R Rao ◽  
James G White
Keyword(s):  
Platelet Aggregation ◽  
Adrenergic Receptors ◽  
Thromboxane A2 ◽  
The Other ◽  
Inhibit Platelet Aggregation ◽  
Activated Platelets ◽  
Arachidonate Metabolism ◽  
Thromboxane Synthetase ◽  
Platelet Disaggregation ◽  
Refractory State

Previous work has shown that platelets irreversibly aggregated by ADP or thrombin (T) can be dissociated by various agents and that the refractory state of disaggregated cells can be reversed immediately by treatment with epinephrine (E). In the present study we have evaluated the influence of drugs which affect different steps in the process of prostaglandin (PG) synthesis on platelet DA-RA. Aspirin and indomethacin did not cause DA of platelets in the process of aggregation nor did they prevent reversal of the refractory state by E and subsequent RA of previously dissociated platelets. Imidazole, which inhibits conversion of endoperoxide to thromboxane A2, also failed to influence DA or restoration of sensitvity and RA of disaggregated platelets. On the other hand, chemicals which interfere with release of AA from the membrane of activated platelets, such as mepacrine, chlorpromazine and trifluoperazine, caused rapid DA. Products of PG synthesis, such as PGE1, PGD2 and PGI2, which usually inhibit platelet aggregation, also caused rapid DA. The refractory state of platelets dissociated from aggregates by most of these agents could be reversed by E treatment. However, trifluoperazine disaggregated platelets could be reaggregated only by the combination of E and AA. Agents which block the a-adrenergic receptors did not cause dissociation of aggregating platelets, but prevented correction of the refractory state of dissociated platelets by E. Thus interference with AA release, even after aggregation, can cause DA of clumped platelets, but blockade of peroxidase, cyclo-oxygenase and thromboxane synthetase do not cause reversal once it is in progress. A membrane linked mechanism associated with AA availability, but not metabolism, regulates DA and restoration of membrane sensitivity for RA.

GPIb is involved in platelet aggregation induced by mucetin, a snake C-type lectin protein from Chinese habu (Trimeresurus mucrosquamatus) venom

2004 ◽  
Vol 91 (06) ◽  
pp. 1168-1176 ◽  
Author(s):  
Qiumin Lu ◽  
Alexei Navdaev ◽  
Jeannine Clemetson ◽  
Kenneth Clemetson
Keyword(s):  
Platelet Aggregation ◽  
Thromboxane A2 ◽  
Platelet Glycoprotein ◽  
Inhibit Platelet Aggregation ◽  
Structural Comparison ◽  
Functional Differences ◽  
Aggregation Response ◽  
Lectin Family ◽  
Lectin Protein ◽  
Induced Aggregation

SummaryMucetin (Trimeresurus mucrosquamatus venom activator, TMVA) is a potent platelet activator purified from Chinese habu (Trimeresurus mucrosquamatus) venom. It belongs to the snake venom heterodimeric C-type lectin family and exists in several multimeric forms. We now show that binding to platelet glycoprotein (GP) Ib is involved in mucetin-induced platelet aggregation. Antibodies against GPIb as well as the GPIb-blocking C-type lectin echicetin inhibited mucetin-induced platelet aggregation. Binding of GPIb was confirmed by affinity chromatography and Western blotting. Antibodies against GPVI inhibited convulxin- but not mucetin-induced aggregation. Signalling by mucetin involved rapid tyrosine phosphorylation of a number of proteins including Syk, Src, LAT and PLCγ2. Mucetininduced phosphorylation of the Fcγ chain of platelet was greatly promoted by inhibition of αIIbβ3 by the peptidomimetic EMD 132338, suggesting that phosphatases downstream of αIIbβ3 activation are involved in dephosphorylation of Fcγ. Unlike other multimeric snake C-type lectins that act via GPIb and only agglutinate platelets, mucetin activates αIIbβ3. Inhibition of αIIbβ3 strongly reduced the aggregation response to mucetin, indicating that activation of αIIbβ3 and binding of fibrinogen are involved in mucetin-induced platelet aggregation. Apyrase and aspirin also inhibit platelet aggregation induced by mucetin, suggesting that ADP and thromboxane A2 are involved in autocrine feedback. Sequence and structural comparison with closely related members of this protein family point to features that may be responsible for the functional differences.

Platelet Activation and Aggregation Induced by Recombinant von Willebrand Factors Reproducing Four Type 2B von Willebrand Disease Missense Mutations

1998 ◽  
Vol 79 (01) ◽  
pp. 211-216 ◽  
Author(s):  
Lysiane Hilbert ◽  
Claudine Mazurier ◽  
Christophe de Romeuf
Keyword(s):  
Platelet Aggregation ◽  
Platelet Activation ◽  
Von Willebrand Disease ◽  
Platelet Glycoprotein ◽  
Missense Mutations ◽  
Inhibit Platelet Aggregation ◽  
Wild Type ◽  
A1 Domain ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryType 2B of von Willebrand disease (vWD) refers to qualitative variants with increased affinity of von Willebrand factor (vWF) for platelet glycoprotein Ib (GPIb). All the mutations responsible for type 2B vWD have been located in the A1 domain of vWF. In this study, various recombinant von Willebrand factors (rvWF) reproducing four type 2B vWD missense mutations were compared to wild-type rvWF (WT-rvWF) for their spontaneous binding to platelets and their capacity to induce platelet activation and aggregation. Our data show that the multimeric pattern of each mutated rvWF is similar to that of WT-rvWF but the extent of spontaneous binding and the capacity to induce platelet activation and aggregation are more important for the R543Q and V553M mutations than for the L697V and A698V mutations. Both the binding of mutated rvWFs to platelets and platelet aggregation induced by type 2B rvWFs are inhibited by monoclonal anti-GPIb and anti-vWF antibodies, inhibitors of vWF binding to platelets in the presence of ristocetin, as well as by aurin tricarboxylic acid. On the other hand, EDTA and a monoclonal antibody directed against GPIIb/IIIa only inhibit platelet aggregation. Furthermore, the incubation of type 2B rvWFs with platelets, under stirring conditions, results in the decrease in high molecular weight vWF multimers in solution, the extent of which appears correlated with that of plasma vWF from type 2B vWD patients harboring the corresponding missense mutation. This study supports that the binding of different mutated type 2B vWFs onto platelet GPIb induces various degrees of platelet activation and aggregation and thus suggests that the phenotypic heterogeneity of type 2B vWD may be related to the nature and/or location of the causative point mutation.

Inhibitory Effect of Staphylokinase on Platelet Aggregation

1993 ◽  
Vol 70 (05) ◽  
pp. 834-837 ◽  
Author(s):  
Akira Suehiro ◽  
Yoshio Oura ◽  
Motoo Ueda ◽  
Eizo Kakishita
Keyword(s):  
Platelet Aggregation ◽  
Human Platelet ◽  
Degradation Products ◽  
Platelet Rich Plasma ◽  
Inhibitory Effect ◽  
Effective Concentration ◽  
Inhibit Platelet Aggregation ◽  
Platelet Suspension ◽  
Washed Platelet ◽  
Human Platelet Aggregation

SummaryWe investigated the effect of staphylokinase (SAK), which has specific thrombolytic properties, on human platelet aggregation. Platelet aggregation induced with collagen was observed following preincubation of platelets in platelet-rich plasma (PRP) or washed platelet suspension (WP) with SAK at 37° C for 30 min. SAK inhibited platelet aggregation in PRP only at the highest examined concentration (1 x 10-4 g/ml). Although SAK did not inhibit platelet aggregation in WP which contained fibrinogen, it did when the platelets had been preincubated with SAK and plasminogen. The most effective concentration in WP was 1 x 10-6 g/ml. The effect could be inhibited by adding aprotinin or α2-antiplasmin. The highest generation of plasmin in the same preincubation fluid was detected at 1 x 10-6 g/ml SAK. We concluded that SAK can inhibit platelet aggregation in WP by generating plasmin and/or fibrinogen degradation products, but is only partially effective in PRP because of the existence of α2-antiplasmin.

The Effects of KBT-3022, a New Anti-platelet Agent, on Hemorheological Properties in Guinea Pigs

1995 ◽  
Vol 73 (01) ◽  
pp. 118-121 ◽  
Author(s):  
Noriko Yamamoto ◽  
Koichi Yokota ◽  
Akira Yamashita ◽  
Minoru Oda
Keyword(s):  
Shear Stress ◽  
Blood Viscosity ◽  
Guinea Pigs ◽  
Direct Action ◽  
Plasma Viscosity ◽  
Fibrinogen Concentration ◽  
Anti Platelet Agent ◽  
Blood Filterability ◽  
2,3 Dpg ◽  
Rbc Deformability

SummaryUsing guinea pigs, a study was conducted on the effects of KBT-3022, a new anti-platelet agent, on hemorheological properties in various tests including blood filterability, blood viscosity, shear stress-induced red blood cell (RBC) deformability and contents of ATP and 2,3-diphosphoglycerate (2,3-DPG). Oral administration of KBT-3022 at 1 and 10 mg/kg significantly increased blood filterability, and significantly reduced blood viscosity at 10 mg/kg without changing the hematocrit, plasma fibrinogen concentration or plasma viscosity. KBT-3022 (10 mg/kg, p.o.) improved RBC deformability in response to shear stress, which was evoked by passing the blood through a thin tube. This dose of KBT-3022 also increased the contents of ATP and 2,3-DPG in RBC. These findings indicate that KBT-3022 may reduce blood viscosity as a sequel to improvement of RBC deformability through direct action on RBC. The increase in the intracellular levels of ATP and 2,3-DPG was considered to be involved in this improvement of hemorheological properties. These hemorheological effects of KBT-3022 appear to be promising for the treatment of patients with ischemic vascular disease.

The Effects of Acute Smoking on Platelet Behaviour, Fibrinolysis and Haemorheology in Habitual Smokers

1984 ◽  
Vol 51 (01) ◽  
pp. 006-008 ◽  
Author(s):  
J J F Belch ◽  
B M McArdle ◽  
P Burns ◽  
G D O Lowe ◽  
C D Forbes
Keyword(s):  
Platelet Aggregation ◽  
Factor Viii ◽  
Plasminogen Activator ◽  
Arterial Thrombosis ◽  
Plasma Viscosity ◽  
Red Cell ◽  
Cell Deformability ◽  
Red Cell Deformability ◽  
Cigarette Smokers ◽  
Smoking Group

SummaryThere is an increased frequency of arterial thrombosis in cigarette smokers. The changes in blood coagulation seen in these subjects have been studied by many workers but results have not always been in agreement. We wished to study the effects of acute .smoking on platelet behaviour, fibrinolysis and haemorheology in ten habitual smokers, and to compare these results with nonsmoking controls. Results show that the smoking group had higher plasma fibrinogen (p <0.04), lower plasminogen (p <0.02) and plasminogen activator (p <0.05), and higher plasma viscosity (p <0.003). The changes seen in cigarette smokers after smoking three cigarettes were an increase in the rate of platelet aggregation to ADP (p <0.02), an increase in α2M, (p <0.02), and factor VIII RAG (p <0.05). Plasma viscosity was decreased (p <0.02) as was red cell deformability (p >0.02).We confirm an increased tendency to hypercoagulability in smokers compared to controls which becomes more pronounced immediately after smoking three cigarettes.

Blood Viscosity and Platelet Aggregation in Male and Female Patients with Transient Ischaemic Attacks (TIA)

1979 ◽  
Author(s):  
G. Palareti ◽  
M. Poggi ◽  
G. Fortunato ◽  
S. Coccheri
Keyword(s):  
Platelet Aggregation ◽  
Blood Viscosity ◽  
Indirect Evidence ◽  
Vascular Lesions ◽  
Transient Ischaemic Attacks ◽  
Group A ◽  
Circulating Platelet Aggregates ◽  
Male Patients ◽  
Group B ◽  
Almost All

A series of 40 patients with TIA (25 males and 15 females) was thoroughly investigated by means of angiography and computerized tomography, and divided into a group (A) of 15 “sine materia”, and a group (B) of 25 with direct or indirect evidence of vascular occlusive or stenotic changes. Blood viscosity at 230 sec-1 37° was cp 4.2 ± 0.3 in the controls, cp 4.7 ± 0.7 in all patients (p < 0.05) cp 4.98 ± 0.7 in all male patients (p < 0.01 versus male controls), and cp 4.75 ± 0.8 in group B (p < 0.02). Haematocrit and Fibrinogen were also significantly increased in all male patients and in group B. Circulating platelet aggregates (CPA) were increased in 40% of the patients. Almost all patients with elevated CPA were males, with a slight prevalence in group B. Changes in blood viscosity parameters and in platelet aggregation in TIA patients were therefore related both to evidence of vascular lesions, and to sex, since they were found to prevail in male patients of both groups.

Sign in / Sign up

Export Citation Format

Share Document